Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Veliparib (ABT-888) in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Locally Advanced, Unresectable Pancreatic Cancer

NCT01908478 is registered in ClinicalTrials.gov with Cedars-Sinai Medical Center as lead sponsor.

NCT NCT01908478
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01908478 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Veliparib (ABT-888) in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Locally Advanced, Unresectable Pancreatic Cancer
Lead sponsor
Cedars-Sinai Medical Center
Phase
Phase 1
Overall status
Completed
Start date
October 2, 2013
Completion date
July 6, 2020
Enrollment
34 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer